Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Retained Earnings (2022 - 2025)

Oramed Pharmaceuticals' Retained Earnings history spans 4 years, with the latest figure at -$123.4 million for Q4 2025.

  • For Q4 2025, Retained Earnings changed N/A year-over-year to -$123.4 million; the TTM value through Dec 2025 reached -$123.4 million, changed N/A, while the annual FY2025 figure was -$123.4 million, N/A changed from the prior year.
  • Retained Earnings reached -$123.4 million in Q4 2025 per ORMP's latest filing, down from -$122.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$122.6 million in Q3 2025 to a low of -$184.3 million in Q1 2025.
  • Average Retained Earnings over 4 years is -$155.7 million, with a median of -$157.6 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: decreased 21.56% in 2023, then rose 26.35% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$163.1 million in 2022, then grew by 3.39% to -$157.6 million in 2023, then fell by 5.63% to -$166.4 million in 2024, then increased by 25.83% to -$123.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Retained Earnings are -$123.4 million (Q4 2025), -$122.6 million (Q3 2025), and -$171.0 million (Q2 2025).